Industry News
News From The Journal Of Clinical Investigation
Jun 05, 2012
METABOLISM Improving obesity-induced insulin sensitivity In recent years, a growing body of evidence has linked inflammation to the development of insulin resistance. In insulin resistance, the hormone insulin is less effective in promoting glucose uptake from the bloodstream into other tissues... Read More
Overcoming Drug Resistance In Cancer
Jun 05, 2012
Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed resistance to these drugs and are therefore no longer responsive to drug treatment... Read More
Clinical Trial Design Supports Original Accelerated Approval Of Sunitinib For GIST
Jun 05, 2012
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in /iClinical Cancer Research, a journal of the American Association for Cancer Research... Read More
Study Of 2 Million Patients Looks At Vena Cava Filters, Outlines Embolism Treatments
Jun 05, 2012
A filter used to block clots from passing from the veins in the legs to the arteries of the lung does not improve mortality rates for most patients suffering a pulmonary embolism. However, if a patient is unstable - in shock or requires a ventilator - filters can save lives... Read More
Study Of 2 Million Patients Looks At Vena Cava Filters, Outlines Embolism Treatments
Jun 05, 2012
A filter used to block clots from passing from the veins in the legs to the arteries of the lung does not improve mortality rates for most patients suffering a pulmonary embolism. However, if a patient is unstable - in shock or requires a ventilator - filters can save lives... Read More
Genentech's Trastuzumab Emtansine (T-DM1) Reduces The Risk Of Cancer Worsening
Jun 04, 2012
Roche announced today that it's division, known as Genentech, has produced positive results in a phase three EMILIA study of a drug called trastuzumab emtansine (T-DM1). Genentech says that the drug met the endpoint target for the trial, showing marked improvement for women with HER2-positive metastatic breast cancer... Read More
Dabrafenib And Trametinib For Metastatic Melanoma Meet Primary Endpoints In Phase III Studies
Jun 04, 2012
Phase III human trials of single agent therapy using dabrafenib and trametinib for patients with BRAF V600 mutation positive metastatic melanoma met their primary endpoints, GSK (GlaxoSmithKline) reported at the Annual Meeting of ASCo (American Society of Clinical Oncology), Chicago, Illinois, today. The trial results were also published today in NEJM (New England Journal of Medicine)... Read More
Promising Biomarkers And New Therapeutic Targets Identified For Kidney Cancer
Jun 04, 2012
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors... Read More
Promising Biomarkers And New Therapeutic Targets Identified For Kidney Cancer
Jun 04, 2012
Using blood, urine and tissue analysis of a unique mouse model, a team led by UC Davis researchers has identified several proteins as diagnostic biomarkers and potential therapeutic targets for kidney cancer. Subject to follow-up validation testing, inhibition of these proteins and several related pathways holds promise as a form of therapy to slow the growth of kidney tumors... Read More
Dual Effect On Tumor Blood Vessels
Jun 04, 2012
As soon as they have grown to pinhead size, tumors rely on the formation of new blood vessels - a process which is scientifically called angiogenesis. Interfering with this process (antiangiogenesis) is considered to be a promising approach in cancer medicine... Read More
Previous Page Next Page